Clarametyx Biosciences
Series A in 2024
Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.